The Body Pharm GHK-Cu 50 Pen is a pre-mixed copper tripeptide research format containing 50 mg of glycyl-L-histidyl-L-lysine-copper, designed for in vitro and preclinical dosing in laboratory settings. For UAE-based research teams, the pen format reduces reconstitution variability and dead-volume losses common to lyophilised vials. Those losses compound across replicate fibroblast or angiogenesis assays, where dosing precision directly affects statistical power.
This guide covers the mechanistic pathways GHK-Cu activates (collagen synthesis, angiogenesis, and dermal wound healing); pen-specific handling under Gulf ambient conditions and cold-chain considerations; and the post-2023 evidence base supporting GHK-Cu's regenerative profile. We have written this for UAE procurement officers and bench scientists evaluating a ghk-cu copper peptide pen for research. Where supplier specifications (per-click volume, batch CoA, HPLC purity) were not independently verifiable at the time of writing, we flag the gap rather than infer figures.
Key Takeaways
- GHK-Cu is an endogenous human tripeptide that coordinates copper(II) and activates collagen synthesis, angiogenesis and wound-healing pathways through redox-mediated gene expression
- The pen format delivers fixed mechanical volumes per click, reducing inter-operator variability compared to manual pipetting from reconstituted vials, but requires verification of per-click dose before protocol lock
- Pre-mixed aqueous GHK-Cu has a shorter in-use window than lyophilised powder and faces higher thermal risk during UAE summer courier transit; specify validated 2–8 °C shipping with temperature loggers
- Research-grade GHK-Cu is not approved by MoHAP for human use; procurement requires institutional laboratory licence, ethics-committee approval and compliance with UAE Federal Law No. 4 of 2016
- Post-2023 peer-reviewed human-fibroblast studies directly measuring collagen gene expression (COL1A1, COL3A1) after GHK-Cu exposure were not identified in supplied sources; mechanistic claims rest on pre-2023 literature
What Is GHK-Cu? A Research-Focused Definition
GHK-Cu is glycyl-L-histidyl-L-lysine copper(II), an endogenous human plasma tripeptide with a molecular weight of approximately 340.38 g/mol. It coordinates a single Cu(II) ion through its histidine imidazole, terminal amine, and adjacent amide nitrogen. This square-planar copper coordination underpins its redox activity and receptor interactions in regenerative signalling. The Cu(II) ion participates in electron-transfer reactions that modulate gene expression.
Linus Pickart first isolated GHK from human plasma albumin in 1973. GHK circulates at roughly 200 ng/mL in the third decade of life and declines to around 80 ng/mL by age 60. This shift correlates with reduced tissue-repair capacity. Lower circulating GHK-Cu levels correlate with impaired collagen remodelling and slower wound closure (Pickart & Margolina, 2018, pre-2023; post-2023 plasma quantification not identified in supplied sources). The complex binds copper with femtomolar-range affinity, which separates it from synthetic copper-peptide analogues such as AHK-Cu or GHK derivatives engineered for cosmetic stability.
Distinguishing GHK-Cu from related research peptides
GHK-Cu sits within a broader regenerative peptide cluster studied for extracellular matrix remodelling and angiogenic signalling. Researchers comparing mechanisms often run parallel arms with TB500 research peptide, which acts via actin sequestration rather than copper-mediated gene modulation, and with IGF-1 LR3, a long-acting analogue used to probe fibroblast proliferation independent of copper coordination. That mechanistic separation matters when designing controls for collagen or wound-closure endpoints, it lets researchers isolate copper-dependent effects from growth-factor-driven proliferation.
Three Core Research Pathways Investigated in 2024–2026
GHK-Cu is currently investigated along three convergent regenerative pathways: collagen synthesis, angiogenesis, and wound healing. Each maps to defined gene and protein endpoints used in in vitro and preclinical models. The 2024–2026 primary literature accessible in the supplied source set is limited. Pre-2023 foundational data is flagged where it remains the strongest available evidence.
Collagen synthesis: COL1A1, COL3A1 and TGF-β1
GHK-Cu is reported to upregulate genes governing fibrillar collagen deposition. COL1A1 and COL3A1 are the principal type I and type III collagen transcripts of interest, alongside TGF-β1 as an upstream modulator. TGF-β1 signalling drives fibroblast differentiation and collagen gene expression. The mechanistic basis derives largely from Pickart & Margolina's 2018 review documenting altered tissue-remodelling gene expression following GHK-Cu exposure. No 2024–2026 peer-reviewed human-fibroblast study directly measuring COL1A1 and COL3A1 after GHK-Cu exposure was identified in the supplied sources. This gene-level claim is historically supported but not refreshed in the current evidence window. Researchers concerned about the age of supporting data should contact the supplier for access to any unpublished 2024–2026 in vitro datasets.
Angiogenesis: VEGF-A and capillary formation
GHK-Cu is associated with VEGF pathway activation and stimulation of capillary tube formation in wound-bed models. VEGF-A drives endothelial cell proliferation and migration, which positions GHK-Cu as a candidate for neovascularisation studies in ischaemic tissue. The angiogenic readouts most commonly designed into protocols are VEGF-A expression, CD31-positive microvessel density, and tube-formation assays in HUVEC (human umbilical vein endothelial cell) cultures. Researchers building parallel arms for vascular endpoints frequently include TB500 research peptide, which drives endothelial migration through actin sequestration rather than copper-mediated transcriptional effects, allowing mechanistic separation in shared assay plates.
Wound healing: MMP-2, MMP-9 and keratinocyte migration
GHK-Cu modulates matrix metalloproteinases, particularly MMP-2 and MMP-9, alongside anti-inflammatory cytokine shifts and keratinocyte migration in scratch-assay formats. MMP activity is essential for extracellular matrix remodelling during the proliferative phase of repair. The 2018 review remains the densest mechanistic summary in the supplied sources, describing GHK-Cu's combined action on protease balance and inflammatory tone during that proliferative phase. For proliferation-focused controls independent of copper coordination, IGF-1 LR3 is commonly run in adjacent wells, isolating growth-factor-driven fibroblast and keratinocyte responses from copper-peptide-specific effects. No post-2023 comparative study contrasting copper-free GHK against GHK-Cu in collagen or wound-closure assays was identified in the supplied sources.
Body Pharm GHK-Cu 50 Pen: Product Specifications
The Body Pharm GHK-Cu 50 Pen is a research-use-only copper tripeptide preparation supplied as a pre-mixed 50 mg fill in a multi-click pen delivery format. It is intended for in vitro and preclinical work where repeat sub-millilitre dispensing is required. The 50 mg load suits multi-replicate dose-response studies or extended research programmes that would otherwise require frequent reconstitution of lyophilised vials.
| Specification | Value |
|---|---|
| Peptide | GHK-Cu (glycyl-L-histidyl-L-lysine copper complex) |
| Total peptide content | 50 mg per pen |
| Format | Pre-mixed multi-click research pen |
| Purity grade | Research-grade (lot-specific CoA required from supplier; HPLC purity not verified in supplied sources) |
| Storage | 2–8 °C; protect from light |
| Recommended use | In vitro and preclinical research only |
Per-click delivered volume and the resulting µg/click dose are not stated in the supplied product sources. Confirm these against the manufacturer's lot documentation before protocol finalisation, because dosing precision directly affects assay reproducibility. UAE procurement officers should request a batch-specific certificate of analysis. No downloadable CoA was located in the public listings reviewed.
Researchers assembling parallel regenerative arms commonly procure TB500 research peptide and IGF-1 LR3 under the same cold-chain conditions to standardise handling across the stack.
Pen Format vs. Lyophilised Vial: Which Suits Your Research Workflow?
The pen format suits high-throughput, repeat-dispensing in vitro work. The lyophilised vial suits long-storage, single-batch protocols where cold-chain integrity cannot be guaranteed. The decision comes down to five practical variables: dosing precision, reconstitution overhead, post-opening stability, transit thermostability, and cost-per-dose at scale.
Dosing precision and reconstitution overhead
A multi-click pen delivers a fixed mechanical volume per actuation, removing the human-factor variance inherent in manual liquid handling. For dose-response matrices requiring 20 or more identical sub-millilitre aliquots, that repeatability shortens assay set-up and tightens technical replicate coefficients of variation (CVs). The trade-off is that the per-click volume for the Body Pharm 50 Pen is not published in the supplied product documentation and should be empirically verified before protocol lock.
My recommended verification: gravimetrically weigh ten sequential clicks dispensed into tared microtubes on a five-decimal balance. Calculate mean volume assuming aqueous density, and confirm CV is below 3% before using the pen as a quantitative dosing device.
Lyophilised vials require reconstitution with bacteriostatic or sterile water. This adds a calculation step and a contamination-risk window, but lets the researcher choose the final concentration to match the assay.
Post-opening stability and UAE cold-chain exposure
Pre-dissolved peptide in a pen has a shorter in-use window than lyophilised powder because hydrolysis and copper-complex dissociation begin once the peptide is in solution. Lyophilised GHK-Cu is generally more thermostable during transit than aqueous formats. Published thermal-stability data above 37 °C for aqueous GHK-Cu was not located in the supplied sources, a real gap for hot-climate procurement planning.
This matters in the UAE. Summer ambient temperatures regularly exceed 40 °C, and last-mile courier vehicles are a known excursion point. A pen that spends two hours in an uninsulated delivery van in July is at materially higher risk than a lyophilised vial under the same conditions; the higher temperature accelerates hydrolysis of the peptide and dissociation of the copper complex. Procurement officers should specify validated 2–8 °C shipping with temperature loggers for any pre-mixed format.
Cost-per-dose for high-replicate studies
For programmes running hundreds of wells per week, the pen's reduced handling time often offsets its shorter use window. For lower-throughput labs, or those running parallel arms with TB500 research peptide and IGF-1 LR3, lyophilised vials offer better storage flexibility across a multi-peptide stack.
Storage and Handling in UAE Conditions
Store the Body Pharm GHK-Cu 50 Pen at 2–8 °C, protected from light. Minimise time at ambient temperature during courier handover. Copper-peptide complexes are photosensitive because UV exposure accelerates dissociation of the Cu²⁺ ion from the GHK tripeptide. The copper-bound form is the bioactive coordination state described in the regenerative-action literature.
Cold-chain risk in the UAE summer
Dubai's July average daily high sits near 41 °C, and unshaded courier compartments routinely exceed 50 °C between 11:00 and 16:00. Specify validated 2–8 °C shipping with an in-box temperature logger. Instruct receiving staff to transfer the pen to a monitored pharmaceutical-grade fridge within 30 minutes of delivery. Post-2023 thermal stability data for aqueous GHK-Cu above 37 °C was not located in the available literature. Prolonged ambient exposure should be treated as a batch-integrity event pending CoA reconfirmation.
Freeze-thaw and in-use limits
Do not freeze the pen. Freezing aqueous copper-peptide solutions risks precipitation of the copper complex and irreversible loss of stoichiometry, the copper ion may separate from the peptide ligand during ice-crystal formation. Limit cumulative time outside refrigeration to under 60 minutes per working session. Wipe the septum with 70% isopropanol before each withdrawal.
Disposal
Dispose of expired pens through your institution's licensed clinical-waste contractor under Dubai Municipality or the relevant emirate-level hazardous-waste protocols. Do not discard in general laboratory waste. Researchers running parallel arms with TB500 research peptide or IGF-1 LR3 should log all three under the same chain-of-custody record.
Regulatory Status in the UAE: What Researchers Must Know
GHK-Cu in the Body Pharm 50 Pen format is a research-use-only chemical. It is not approved by the Ministry of Health and Prevention (MoHAP) for human administration, cosmetic formulation at this concentration, or any therapeutic indication. Procurement, storage and in vitro use fall under UAE Federal Law No. 4 of 2016 on Medical Products, Pharmacy Practice and Pharmaceutical Establishments, which governs the import, handling and onward transfer of pharmaceutical and pharmaceutical-adjacent substances within the Emirates.
Before placing an order, confirm three institutional prerequisites:
- A valid laboratory licence issued under the relevant emirate's health authority
- Written ethics-committee approval for the specific study protocol
- A documented chain-of-custody procedure covering receipt, refrigerated storage and disposal
The distinction between research-grade peptide (sold against a batch CoA for in vitro work) and pharmaceutical-grade peptide (manufactured under Good Manufacturing Practice (GMP) for human use) is material. Research-grade materials are not subject to the same manufacturing controls and purity assurance as pharmaceutical-grade compounds. The pen format discussed here is the former. The MoHAP scheduling position for GHK-Cu specifically was not confirmed in the sources available at the time of writing. Verify current status with MoHAP or your institution's regulatory affairs office before import.
Research-use disclaimer
For laboratory research use only. Not for human or veterinary consumption, injection, ingestion or topical application. Not a food, cosmetic, supplement or medicinal product. Sale, supply and handling are restricted to qualified researchers operating under institutional licence and ethics approval in accordance with UAE Federal Law No. 4 of 2016.
Researchers stacking comparative arms with TB500 research peptide or IGF-1 LR3 must list each compound separately on the ethics submission. Blanket approvals covering "regenerative peptides" are not accepted by most UAE institutional review boards.
Related Peptides for Regenerative Research
GHK-Cu rarely appears in isolation within a regenerative research programme. Researchers typically study it alongside peptides targeting complementary repair pathways. The three most commonly paired compounds in UAE laboratory stacks are TB500, IGF-1 LR3 and MOTS-C, each addressing a distinct mechanistic axis.
TB500 research peptide is a synthetic fragment of thymosin beta-4 investigated for its role in G-actin sequestration and cell migration during tissue repair. It is a natural comparator in wound-healing assays where GHK-Cu's matrix-remodelling effects are measured. IGF-1 LR3 is studied for sustained insulin-like growth factor-1 (IGF-1) receptor activation and downstream phosphatidylinositol 3-kinase (PI3K)/Akt signalling relevant to fibroblast and myoblast proliferation. It is often run as a parallel arm when quantifying proliferative versus structural contributions to repair. MOTS-C is a 16-amino-acid mitochondrial-derived peptide examined for adenosine monophosphate-activated protein kinase (AMPK)-mediated metabolic regulation and cellular stress tolerance, providing a bioenergetic counterpoint to GHK-Cu's extracellular matrix focus.
In practice, researchers designing multi-arm in vitro studies treat each peptide as a separate ethics-submission entry, with independent reconstitution, storage and CoA documentation per the institutional requirements outlined earlier.
Frequently Asked Questions
What is the purity of the Body Pharm GHK-Cu 50 Pen?
Body Pharm markets the GHK-Cu 50 Pen as a research-grade copper tripeptide, but a specific HPLC purity percentage is not published in materials accessible to us at the time of writing. Request the lot-specific certificate of analysis from the supplier before procurement and verify purity meets the ≥98% threshold typically required for in vitro work. Lower purity introduces uncharacterised contaminants that may confound gene-expression or cell-migration endpoints.
How is the pen shipped to UAE addresses?
Pen-format GHK-Cu is generally dispatched as a tracked, temperature-controlled parcel with discreet outer packaging, consistent with research-chemical shipping practice in the European supplier network. UAE-bound consignments should be coordinated with a customs broker familiar with research-use-only peptides. MoHAP classification of GHK-Cu as a research chemical has not been confirmed in a primary regulatory document and should be verified by the procurement officer before order placement.
Can GHK-Cu be used in cell culture assays?
Yes. GHK-Cu is widely used in in vitro fibroblast, keratinocyte and endothelial cell models to study collagen synthesis, angiogenesis and matrix remodelling. Reconstitution into a sterile aqueous vehicle, followed by 0.22 µm filtration before addition to culture media, is standard practice. Filtration removes particulates and ensures sterility. Copper-bound formulations require attention to media chelators that may compete for the Cu²⁺ ion.
What is the difference between GHK and GHK-Cu?
GHK is the free glycyl-L-histidyl-L-lysine tripeptide. GHK-Cu is the same sequence bound to a copper(II) ion. The copper-bound form is the biologically active complex referenced in regenerative and gene-modulation studies because the Cu²⁺ ion participates in redox reactions that modulate gene expression. Comparative assays of copper-free versus copper-bound GHK in collagen synthesis are reported in older literature. No post-2023 primary comparative study was identified in the sources consulted for this guide.
Is a certificate of analysis (CoA) available?
A batch-specific CoA should be requested directly from Body Pharm or the authorised reseller prior to purchase. CoA provision is standard for research-grade peptides used alongside compounds such as TB500 research peptide and IGF-1 LR3 in regenerative stacks, documenting purity, identity and microbial limits for each batch.
Next Steps
Before procurement, contact Body Pharm directly to obtain the lot-specific certificate of analysis and confirm the per-click delivered volume for the 50 Pen. Verify current MoHAP regulatory status for GHK-Cu with your institution's regulatory affairs office. If your laboratory is new to copper-peptide handling, request a thermal-stability datasheet covering storage above 25 °C to inform your cold-chain specification. Once you have confirmed purity, dosing precision and regulatory clearance, coordinate with your institution's ethics committee to submit a protocol-specific approval covering GHK-Cu and any parallel peptides such as TB500 or IGF-1 LR3. This ensures compliance with UAE Federal Law No. 4 of 2016 and positions your research team for reproducible, auditable in vitro work.
